Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells (NCT03554889) | Clinical Trial Compass
UnknownPhase 1
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
China21 participantsStarted 2018-08-01
Plain-language summary
NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies. NK also express an activating Fc receptor that mediates antibody-dependent cellular cytotoxicity (ADCC) and production of immune modulatory cytokines in response to antibody-coated targets. Nimotuzumab, an monoclonal antibody against EGFR (epidermal growth factor receptor), may enhance the ADCC effect of NK cell. This study will evaluate the safety of combination of nimotuzumab and NK Cell in treating advanced cancer patients. Blood samples will also be collected for research purposes.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Histologically confirmed recurrent or metastatic cancer
✓. Measurable disease
✓. Progressed after all standard treatment
✓. ECOG performance status of 0 to 2
✓. Expected life span ≥ 3 months
✓. Toxicities from prior treatment has resolved. Washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy
✓. Major organs function normally
✓. Women at pregnant ages should be under contraception
Exclusion criteria
✕. Other malignancy within 5 years prior to entry into the study, expect for treated non melanoma skin cancer and cervical carcinoma in situ